Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher P Cannon

Showing results (381-390 of 706) with videos related to

Pageof 71
Sort By:
Circulation|April 17, 2002
Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptideMarc S Sabatine, David A Morrow, James A de Lemos, et al.
The American Journal of Cardiology|October 29, 2005
Intensity of lipid lowering with statins and brachial artery vascular endothelium reactivity after acute coronary syndromes (from the BRAVER trial)Jocelyn Dupuis, Jean-Claude Tardif, Jean-Lucien Rouleau, et al.
American Heart Journal|May 16, 2016
Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trialYuichi J Shimada, Christopher P Cannon, Yuyin Liu, et al.
Clinical Cardiology|June 15, 2021
Kidney outcomes using a sustained ≥40% decline in eGFR: A meta-analysis of SGLT2 inhibitor trialsDavid Z I Cherney, Samuel Dagogo-Jack, Darren K McGuire, et al.
Sleep & Breathing = Schlaf & Atmung|May 20, 2022
Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trialBrian S Wojeck, Silvio E Inzucchi, Ian J Neeland, et al.
The American Journal of Cardiology|April 26, 2008
Relation of hyperemic epicardial flow to outcomes among patients with ST-segment elevation myocardial infarction receiving fibrinolytic therapyC Michael Gibson, Yuri B Pride, Jacqueline L Buros, et al.
Journal of the American Heart Association|October 30, 2018
Lower On-Treatment Low-Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab TrialsAntonio J Vallejo-Vaz, Henry N Ginsberg, Michael H Davidson, et al.
American Heart Journal|December 12, 2017
Association of insurance type with receipt of oral anticoagulation in insured patients with atrial fibrillation: A report from the American College of Cardiology NCDR PINNACLE registryCelina M Yong, Yuyin Liu, Patricia Apruzzese, et al.
The American Journal of Cardiology|March 23, 2011
Effect of prior stroke on the use of evidence-based therapies and in-hospital outcomes in patients with myocardial infarction (from the NCDR ACTION GWTG registry)Farhad Abtahian, Benjamin Olenchock, Fang-Shu Ou, et al.
Journal of the American Heart Association|August 9, 2021
What Do US Physicians and Patients Think About Lipid-Lowering Therapy and Goals of Treatment? Results From the GOULD RegistrySuzanne V Arnold, Christopher P Cannon, James A de Lemos, et al.
Pageof 71

Showing results (381-390 of 706) with videos related to

Sort By:
Pageof 71
Circulation|April 17, 2002
Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptideMarc S Sabatine, David A Morrow, James A de Lemos, et al.
The American Journal of Cardiology|October 29, 2005
Intensity of lipid lowering with statins and brachial artery vascular endothelium reactivity after acute coronary syndromes (from the BRAVER trial)Jocelyn Dupuis, Jean-Claude Tardif, Jean-Lucien Rouleau, et al.
American Heart Journal|May 16, 2016
Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trialYuichi J Shimada, Christopher P Cannon, Yuyin Liu, et al.
Clinical Cardiology|June 15, 2021
Kidney outcomes using a sustained ≥40% decline in eGFR: A meta-analysis of SGLT2 inhibitor trialsDavid Z I Cherney, Samuel Dagogo-Jack, Darren K McGuire, et al.
Sleep & Breathing = Schlaf & Atmung|May 20, 2022
Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trialBrian S Wojeck, Silvio E Inzucchi, Ian J Neeland, et al.
The American Journal of Cardiology|April 26, 2008
Relation of hyperemic epicardial flow to outcomes among patients with ST-segment elevation myocardial infarction receiving fibrinolytic therapyC Michael Gibson, Yuri B Pride, Jacqueline L Buros, et al.
Journal of the American Heart Association|October 30, 2018
Lower On-Treatment Low-Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab TrialsAntonio J Vallejo-Vaz, Henry N Ginsberg, Michael H Davidson, et al.
American Heart Journal|December 12, 2017
Association of insurance type with receipt of oral anticoagulation in insured patients with atrial fibrillation: A report from the American College of Cardiology NCDR PINNACLE registryCelina M Yong, Yuyin Liu, Patricia Apruzzese, et al.
The American Journal of Cardiology|March 23, 2011
Effect of prior stroke on the use of evidence-based therapies and in-hospital outcomes in patients with myocardial infarction (from the NCDR ACTION GWTG registry)Farhad Abtahian, Benjamin Olenchock, Fang-Shu Ou, et al.
Journal of the American Heart Association|August 9, 2021
What Do US Physicians and Patients Think About Lipid-Lowering Therapy and Goals of Treatment? Results From the GOULD RegistrySuzanne V Arnold, Christopher P Cannon, James A de Lemos, et al.
Pageof 71